University of Cambridge
New blood tests could transform how dementia is diagnosed — making it faster, simpler, and more accessible. We want to understand how people feel about these tests and what matters when deciding whether to take one.
About this project
This survey is part of the READ-OUT (REAl-world Dementia OUTcomes) programme. We aim to understand public and patient views on new blood tests for dementia and other memory problems. You will be asked about whether you would consider taking such a test, and what factors influence your decision. Your responses will help ensure these tests are introduced in ways that are appropriate, acceptable, and beneficial.
Why this matters?
Around one in three people with dementia never receive a formal diagnosis. Current diagnostic pathways can be slow, complex, and difficult to access. Earlier and more accurate diagnosis could:
- Help people access support sooner
- Enable better care planning
- Open opportunities for new treatments and research participation
- Blood tests have the potential to significantly improve this process
What will happen?
If you take part:
- You will complete a short online survey (around 10-15 minutes)
- You will be asked about your views on dementia and blood testing
- Some questions are hypothetical (there are no right or wrong answers)
- Your responses are anonymous and confidential
Who can take part?
We are inviting:
- Adults aged 18 or over
- People with or without experience of dementia
- Anyone interested in sharing their views on health and screening
More about READOUT
READ-OUT (REAl-world Dementia OUTcomes) is a UK-wide research programme exploring how new blood tests could improve the diagnosis of dementia.
These tests have shown promise in research, and this study aims to understand how well they work in real-world settings and how they could be used in the NHS in the future.
Understanding the blood biomarkers for dementia?
Blood tests for dementia are a new type of test that aim to detect changes in the body linked to brain health.
Instead of relying only on memory tests or brain scans, these tests use a small blood sample to look for biological markers (often called “biomarkers”) associated with conditions like Alzheimer’s disease. They are still being studied, but they may make diagnosis faster, simpler, and more accessible in the future.